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Abstract
There is considerable evidence that human genetic variation influences gene expression. Genome-wide studies have
revealed that mRNA levels are associated with genetic variation in or close to the gene coding for those mRNA transcripts –
cis effects, and elsewhere in the genome – trans effects. The role of genetic variation in determining protein levels has not
been systematically assessed. Using a genome-wide association approach we show that common genetic variation
influences levels of clinically relevant proteins in human serum and plasma. We evaluated the role of 496,032
polymorphisms on levels of 42 proteins measured in 1200 fasting individuals from the population based InCHIANTI study.
Proteins included insulin, several interleukins, adipokines, chemokines, and liver function markers that are implicated in
many common diseases including metabolic, inflammatory, and infectious conditions. We identified eight Cis effects,
including variants in or near the IL6R (p = 1.8610257), CCL4L1 (p = 3.9610221), IL18 (p = 6.8610213), LPA (p = 4.4610210),
GGT1 (p = 1.561027), SHBG (p = 3.161027), CRP (p = 6.461026) and IL1RN (p = 7.361026) genes, all associated with their
respective protein products with effect sizes ranging from 0.19 to 0.69 standard deviations per allele. Mechanisms
implicated include altered rates of cleavage of bound to unbound soluble receptor (IL6R), altered secretion rates of different
sized proteins (LPA), variation in gene copy number (CCL4L1) and altered transcription (GGT1). We identified one novel trans
effect that was an association between ABO blood group and tumour necrosis factor alpha (TNF-alpha) levels
(p = 6.8610240), but this finding was not present when TNF-alpha was measured using a different assay , or in a second
study, suggesting an assay-specific association. Our results show that protein levels share some of the features of the
genetics of gene expression. These include the presence of strong genetic effects in cis locations. The identification of
protein quantitative trait loci (pQTLs) may be a powerful complementary method of improving our understanding of
disease pathways.
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Introduction
The identification of gene variants that alter the risk of common
diseases has proven difficult. Recent genome-wide association
studies of disease cases and controls have improved this situation
but have shown that, with a few exceptions, most genetic effects on
common disease are likely to be small [1].
One successful complementary approach to studying gene-
disease associations is to study associations between genetic
variation and gene expression. Several genome-wide studies have
shown that genetic variation influences gene expression [2–8].
Most of these gene regions or variants are found in or close to the
gene that codes for the mRNA product (cis effects), whilst others
are found elsewhere in the genome (trans effects). The identification
of these effects on gene expression may help understand disease
aetiology. However, these data are limited by the fact that they
assess gene expression, usually from a single cell type, rather than
protein levels, which are likely to be more directly implicated in
disease processes [9].
There are no genome-wide analyses of the role of human
genetic variation on large numbers of proteins. One way of testing
this, and a way that could be relevant to the understanding of
human diseases, is in vivo studies of serum and plasma levels of
proteins. There are likely to be many factors that influence
serum and plasma protein levels, only one of which is genetic DNA
variation leading to differences in mRNA transcription and
subsequent mRNA translation to protein. Other mechanisms
could include epigenetic factors, stochastic factors, environmental
factors influencing regulation of expression, rates of secretion
into the blood from the site of synthesis, proteolysis and
clearance, and post-translational modifications such as glycosyla-
tion.
In this study we tested the hypothesis that common genetic
variation influences protein levels in a human population. We used
1200 European individuals from the population based In-
CHIANTI study[10] with fasting measures of 42 proteins
available. The proteins included many implicated in common
diseases and conditions including inflammatory cytokines such as
interleukins (metabolic and inflammatory conditions), insulin
(diabetes), chemokines (e.g. macrophage inflammatory protein
beta, implicated in HIV progression to AIDs), adipokines (e.g.
adiponectin, leptin, resistin, implicated in metabolic conditions)
and liver function markers. Summary details of individuals and
traits are given in Table 1 and Table S1.
Results
We used data from 496,032 single nucleotide polymorphisms
(SNPs) from across the autosomal genome with minor allele
frequencies .1% and which had passed stringent quality control
checks (see methods). These SNPs captured 80.5% and 86.5% of
European genetic variation, based on HapMap data with minor
allele frequencies .1% and .5% respectively at r2.0.8.
We separated our results into cis effects and trans effects. Cis
effects were defined as those in the gene(s) coding for the protein or
within 300 kb either side of that gene. This was based on a recent
study of HapMap variation in relation to gene expression that
showed that most cis expression effects occur within this distance
of genes [5]. An analysis of all SNPs within a 1Mb window either
side of each gene was consistent with this (Figure 1). We used a p
value cut off that related to the number of SNPs in or within
300 kb of the gene. If, for example, there were 100 SNPs in a gene
region we used 0.05/100= 0.0005 as significant association. We
identified eight cis effects that remained after correction for
Table 1. Basic characteristics of the InCHIANTI study population.
Characteristic N Mean (95% CI) or Percentage
Age (years): Age range 1200 68.4 (67.5–69.3): 21–102
Gender (%female) 1200 55.2%
BMI: BMI range 1131 27.12 (26.87–27.36): 17.99–46.57
Current Smokers (%) 1200 18.80%
Hypertension (via blood pressure tests) (% case) 1176 42.60%
Ever taken drugs for hypertension (current and/or former) 927 38.40%
Diabetes (% case) 1200 11.10%
Myocardial Infarction (% case) 1200 4.00%
Use of Lipid lowering treatment in last 5 years 1167 5.60%
Use of Steroids in last 5 years 1174 8.00%
doi:10.1371/journal.pgen.1000072.t001
Author Summary
One of the central dogmas of molecular genetics is that
DNA is transcribed to RNA which is translated to protein
and alterations to proteins can influence human diseases.
Genome-wide association studies have recently revealed
many new DNA variants that influence human diseases. To
complement these efforts, several genome-wide studies
have established that DNA variation influences mRNA
expression levels. Loci influencing mRNA levels have been
termed ‘‘eQTLs’’. In this study we have performed the first
genome-wide association study of the third piece in this
jigsaw – the role of DNA variation in relation to protein
levels, or ‘‘pQTLs’’. We analysed 42 proteins measured in
blood fractions from the InCHIANTI study. We identified
eight cis effects including common variants in or near the
IL6R, CCL4, IL18, LPA, GGT1, SHBG, CRP and IL1RN genes, all
associated with blood levels of their respective protein
products. Mechanisms implicated included altered tran-
scription (GGT1) but also rates of cleavage of bound to
unbound soluble receptor (IL6R), altered secretion rates of
different sized proteins (LPA) and variation in gene copy
number (CCL4). Blood levels of many of these proteins are
correlated with human diseases and the identification of
‘‘pQTLs’’ may in turn help our understanding of disease.
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multiple testing at p,0.05, using 300 kb each side of the relevant
gene (Table 2 and Figure 2, Figure S1a). Using 100,000
permutations of the phenotype versus region-wide genotype data
confirmed the associations as empirically significant. Given the
uncertainty of using 300 kb each side of a gene to define cis effects
we repeated these eight analyses using 1Mb of flanking sequence
each side of the gene and in each case the association remained
(p,0.05).
For three of the eight genes showing cis effects, the associations
have been reported in other studies, as part of candidate gene
approaches. Variants in or close to the interleukin 6 receptor
(IL6R) and C-reactive protein (CRP) genes, are closely correlated
with those previously reported [11–13](r2 0.96 and 0.91 for IL6R
and CRP respectively) and are associated with 0.69 (95%CIs:0.62–
0.77), and 0.20 (95%CIs:0.12–0.29) per allele standard deviation
differences in their respective protein levels. The SNP in the sex-
hormone binding globulin (SHBG) gene, rs6761, was associated
with SHBG protein levels with a per-allele effect size of 0.21
(95%CIs:0.13–0.30) standard deviations. This association ap-
peared to be independent of a previously reported variant,
rs1799941 [14,15]. These two SNPs are in moderate linkage
disequilibrium (LD) with each other (r2 = 0.1) and both remain
associated with SHBG levels in the InCHIANTI study when
correcting for the presence of the other (p = 0.008 for rs6761
correcting for rs1799941 and p= 0.003 for rs1799941 correcting
for rs6761). We therefore genotyped these two variants in an
additional 4590 individuals from the WATTs (n= 546) and the
The Northern Finland 1966 Birth Cohort (NFBC1966, n = 4044)
studies. Details of replication studies are given in Table S2. The
association between rs1799941 and SHBG levels replicated
(p = 1.4610212) and meta-analysis of all three studies provided
very strong evidence of association (p= 1.8610216). Conditional
analyses using all three studies showed that the association was
driven by rs1799941 (p = 1.6610213 correcting for rs6761) rather
than rs6761 (p = 0.38 correcting for rs1799941).
Five of the cis findings have not been reported in other studies,
although we recently reported those in the interleukin18
(IL18)[16] and interleukin1 receptor antagonist (IL1RN) [17]genes
in the InCHIANTI study as part of candidate gene studies. The
effect sizes of the most strongly associated variants in the
interleukin18 (IL18) and interleukin1 receptor antagonist (IL1RN)
genes were 0.28 (95%CIs:0.20–0.35) and 0.19 (95%CIs:0.11–0.28)
per allele SD differences in their respective protein levels. A novel
cis association was that in the gamma-glutamyltransferase 1
(GGT1) gene. Each minor allele of rs5751901 was associated with
a 0.21 (95%CIs:0.13–0.29) standard deviation increase in GGT1
levels. Other novel cis findings included those in the CCL4 gene
cluster with levels of the protein product macrophage inflamma-
tory protein beta (MIP-1beta). Each minor allele of rs4796217 was
associated with a 0.49 (95%CIs:0.41–0.32) SD decrease in MIP-
Figure 1. Association of SNPs 1Megabase from each cis gene.
For each SNP the X axis represents the distance in base pairs from either
the 59 or 39 end of the gene. If SNPs occur within the gene, either in
introns or exons, they are given a distance of zero. SNPs in IL6R
,1610225 not shown.
doi:10.1371/journal.pgen.1000072.g001
Table 2. Details of Cis and trans effects.
Protein (units) Gene SNP MAF
Distance
(bp) Mean trait values GC P Perm P
11 12 22
TNFa (pg/ml) ABO rs505922 0.34 intron 2.68 (2.53–2.85) 1.66 (1.61–1.72) 1.71 (1.59–1.84) 6.76610240 ,0.0001
IL-6sR (ng/ml) IL6R rs4129267 0.37 intron 69.92 (66.95–72.99) 100.65 (96.97–104.44) 138.13 (129.94–146.77) 1.82610257 ,0.00001
MIPb (pg/ml) CCL4L2 rs4796217 0.34 227353 74.74 (68.85–81.03) 53.32 (48.64–58.34) 27.21 (21.48–33.83) 3.87610221 ,0.00001
IL18 (ug/ml) IL18 rs2250417 0.44 50476 406.79 (392.66–421.43) 366.58 (355.39–378.12) 330.73 (315.83–346.33) 6.79610213 ,0.00001
LPA (mg/dl) LPA rs7770628 0.49 intron 0.34/0.18 0.46/0.52 0.20/0.30 4.36610210 ,0.00001
GGT1 (u/l) GGT1 rs5751901 0.39 6917 17.86 (17.11–18.67) 19.6 (18.85–20.41) 21.38 (19.88–23.07) 1.5261027 0.00076
SHBG (nmol/l) SHBG rs6761* 0.31 115829 111.67 (106.77–116.77) 100.9 (96.55–105.43) 85.16 (77.65–93.31) 3.0861027 ,0.00001
CRP (ug/ml) CRP rs12093699 0.29 34092 2.26 (2.07–2.47) 2.74 (2.48–3.03) 3.64 (2.77–4.78) 6.3661026 0.0038
IL1RA (pg/ml) IL1RN rs6761276 0.37 43158 118.6 (112.49–125.05) 142.16 (135.73–148.89) 141.23 (126.74–157.37) 7.2761026 0.00097
MAF=minor allele frequency, SNP = single nucleotide polymorphism and represents the best p value. Distance represents the distance from the gene or location within
gene.
GC P represents the p value corrected for inflation factors but not multiple testing. Mean trait values are back transformed values from transformed means, except for
LPA where frequencies of genotypes in the low (first value) and high (second value) level groups are given. 11 = common hom, 12 = het, 22 =minor allele homozygote.
Perm=Permutation.
P values based on 100,000 region wide (gene +-300 kb) permutations for cis effects and 10,000 genome-wide permutations for trans effects (‘‘,’’ indicates the observed
p value did not occur in these numbers of permutations). *Further analysis shows that this signal is driven by a SNP, rs1799941, in partial LD with rs6761 – see text.
doi:10.1371/journal.pgen.1000072.t002
Genome-Wide Analysis of Protein Levels
PLoS Genetics | www.plosgenetics.org 3 May 2008 | Volume 4 | Issue 5 | e1000072
1beta levels. The association in the LPA gene resulted in a per
allele odds ratio of 1.71 (95%CIs:1.45–2.02) for having LPA levels
.14 mg/dl (46% of participants) compared to participants with
LPA levels ,14 mg/dl. Two further cis findings are worth noting
although they did not stand up to all methods of testing. The third
strongest association from across the genome with GP130 levels
was in the gene, IL6 signal transducer, that encodes the GP130
protein (rs11574783, p = 6.961026). A SNP in the parathyroid
Figure 2. Cis genotype effects. X axis shows the distance on the relevant chromosome. Left hand Y axis shows the2log10 p values and right hand
Y axis shows the recombination rate as calculated from HapMap data.
doi:10.1371/journal.pgen.1000072.g002
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hormone (PTH) gene region was associated with PTH levels
(rs2170436, p = 6.361025). Full details of the best cis association
for each of the 42 protein levels measured are shown in Table S3a.
We identified one trans effect after a conservative correction for
multiple testing based on the number of genome-wide SNPs and
phenotypes tested (0.05/(496,032642) = 2.461029) and permuta-
tion testing. Specifically, we identified a polymorphism (rs505922)
close to the ABO blood group gene, that was very strongly
associated with serum TNF-alpha levels (p = 6.76610240) (Table 2,
Figure S1b). Using 100,000 permutations of the phenotype versus
genome-wide genotype data confirmed the association as empir-
ically significant. Closer inspection of this region revealed another
SNP (rs8176746) independently associated with TNF-alpha levels
and haplotypes formed by the two SNPs were correlated (r2 = 0.82)
with the three alleles that determine the A, B and O alleles of ABO
blood group. Separate genotyping of an additional SNP allowed us
to accurately recode individuals with their ABO blood group
based on a two SNP haplotype (rs8176746 and rs8176719) (Figure
S2). Individuals of blood group O (40%) had TNF-alpha levels
0.86 (95%CIs:0.75–0.97) standard deviations (SD) higher than
others. This association appears to be assay specific. Using a
second TNF-alpha assay, made by a different company (Luminex)
resulted in measures of TNF-alpha that were poorly correlated
(r = 0.16, Figure S3a) with those from the first assay (R&D systems
HSTA00C, ultra-sensitive ELISA), although each was strongly
correlated with other inflammatory markers such as C-reactive
protein and Interleukin 6 (Figure S3b). There was no association
between ABO blood group and the Luminex measure of TNF-
alpha (p= 0.26 O blood group vs other blood groups) (Figure S3c)
and no association using a third assay (R&D systems HSTA50
ultra-sensitive ELISA) in a separate group of 1620 white
individuals from the Health ABC study (p= 0.60, O blood group
vs other blood groups). In InCHIANTI there was no strong
evidence that rs505922 was associated with any of the other
protein markers (p.0.001). Full details of the best trans association
for each of the 42 protein levels measured are shown in Table S3b.
Six of the nine associations relate to proteins correlated with
inflammatory or metabolic based disease processes so we further
tested the robustness of the associations in InCHIANTI when
correcting for a number of further covariates, including presence
of cardio-vascular disease, diabetes, smoking status and use of
steroid anti-inflammatory or lipid-lowering drugs. We also
additionally corrected for total protein levels. All associations
remained with very similar effect sizes (Table S4).
We next assessed the likely mechanisms of the cis effects.
Positions of SNP-protein-level associations relative to genes are
shown in Figure 2 and Table S5. For most of the effects, the
correlation between SNPs due to linkage disequilibrium does not
allow us to draw any conclusions about whether the effects are due
to functional variants 5 prime, 3 prime, or within genes. The
mechanism of the association between common variation in the
IL6R gene and soluble interleukin-6 receptor levels is known: an
amino acid substitution Asp358Ala results in differential proteol-
ysis, or ‘‘shedding’’ of the membrane bound to the soluble form of
the IL6r protein[18]. The mechanism of the association between
common variation in the LPA and CCL4 gene regions and their
protein products may be related to copy number variation in these
genes. The LPA finding may be due to the previously described
association of different numbers of ‘‘kringle’’ repeats that result in
different sized proteins [19–21], affecting secretion rates from the
liver [22]. The MIP-1beta finding may be due to different copy
numbers of the CCL4L1 gene. Previous studies have shown that
there are copy number variants, in the form of several copies of the
CCL3L1 and CCL4L1 genes, in this region and it is possible that
the variants we have found are in linkage disequilibrium with
copies of the CCL4L1 gene. Copy number variation of the
CCL3L1 gene, has been associated with progression from HIV
infection to AIDs[23,24] although the role of CCL4L1 gene
variation is not known. For the remaining cis effects one of the
most likely mechanisms is that DNA variation alters gene
expression which in turn alters protein levels. To look for effects
of cis SNPs on gene expression we searched a database of
transcript levels of genes in transformed lymphocytes from a
recently described genome-wide association study[25]. The SNP
associated with GGT1 serum protein levels in our study
(rs5751901) was correlated with a SNP that is associated with
GGT1 transcript abundance (rs6519519) (p = 2.461025) at
r2 = 0.71. This suggests that the GGT1 association we have seen
with protein levels is due to altered transcript levels. There was no
evidence that SNPs near the other genes were associated with
altered transcript levels (p.0.001), although data were not
available from rs1799941.
We next looked more extensively at the publicly available
mRNA data [25] to assess the relationship between gene
expression in lymphocytes and protein levels. For each of the 42
proteins we looked for any SNPs within 300 kb of the protein
coding gene that were associated with transcript levels of that gene
above the genome-wide level of statistical significance
(LOD.6.08) [25]. For one protein measured in InCHIANTI,
IL1beta, there was a cis SNP, rs1143627, associated with transcript
levels at LOD=6.1. However, there was no association between
this signal and serum protein levels, based on a SNP, rs10169916,
in very strong linkage disequilibrium with rs1143627 (r2 = 0.96, p
value with serum protein levels = 0.54).
Discussion
Our study shows that the human genetics of serum and plasma
protein levels share several features of the genetics of gene
expression levels [26]. First, protein levels can be strongly
influenced by common genetic variation. This has been shown
before for some proteins, notably common null alleles in the
enzymes GSTM1 and GSTT1 are associated with a lack of
product [27,28], but our study provides the first systematic,
genome-wide assessment of the role of genetic variation on human
protein levels. The effect sizes we observe are relatively large
(,0.19 to ,0.69 SDs per allele) compared to reproducible effects
of common variation on other human quantitative traits such as
height[29] and body mass index[30]. This does not rule out the
presence of weaker effects that did not reach our statistical
thresholds. Second, protein quantitative trait loci (pQTLs) can be
successfully mapped using a genome-wide association approach,
although fine-mapping and functional studies are needed to
narrow down the most likely functional variants for most of these
traits. Third, there are cis effects and these cis effects are often the
strongest in the genome. Further studies are needed to investigate
the one trans finding we identified with TNF-alpha using one assay
but not others. We did not find evidence for a fourth feature
highlighted by genetic studies of gene expression: we did not find
any ‘‘multi-trans’’ effects, where gene variants are associated with
levels of multiple proteins.
It is likely that there are other cis effects that did not reach our
cut off for significance. The need to correct p values for the
number of tests performed meant that our study was not well
powered to detect cis effects less than ,0.22 or ,0.18 standard
deviations per allele for minor allele frequencies 0.1 and 0.5
respectively (based on p=0.0005). Known variants that did not
reach our criteria included those in the FGB (fibrinogen beta chain)
Genome-Wide Analysis of Protein Levels
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and CCL2 genes, known to alter levels of their protein products,
fibrinogen[31] and MCP [32], respectively, but which only
reached nominal evidence for association in our data. (rs6056 in
the FGB gene p= 0.051 and rs1024611 in CCL2 p= 0.02).
Additional trans effects may also exist but the need to correct for
both the genome-wide number of SNPs and number of
phenotypes meant that our study would not have detected effects
less than ,0.30 standard deviations per allele (based on
p= 2.461029). Given that our Bonferroni-based statistical cut-offs
are likely to be conservative we also calculated false discovery rates
[33]. For all 496,032 tests across 42 phenotypes we estimated that
5%, 10% and 20% of findings will be false discoveries at p values
of ,161027, ,3.61027 and ,1.061026 respectively.
For one of the eight cis findings, the mechanism is known –
differential cleavage of bound to unbound receptor caused by an
amino acid changing SNP (nsSNP) results in different levels of
soluble IL6 receptor [18]. For two other cis findings the
associations may relate to copy number variants (CNVs). There
are reports that different sized LPA proteins, caused by different
numbers of kringle repeats, are likely to result in altered secretion
rates from the liver into the blood stream [22]. It is also likely that
the MIP-beta finding is caused by copy number variation of the
CCL4L1 gene, although further studies are needed to assess the
extent of linkage disequilibrium between the LPA and CCL4L1-
region variants we have found and CNVs in these genes. For the
remaining cis effects, we have found little correlation between
SNPs altering gene expression levels in lymphocytes and protein
levels, with the exception of the GGT1 finding. This is perhaps not
surprising given the numerous processes that could influence
protein levels and is consistent with the observation in yeast
experiments that there is considerable variation in the correlation
between expression levels and protein abundance[34–37]. For
many of our findings, the unstimulated cultured lymphocytes used
in the gene expression experiment [8] may not be the most
relevant tissue to use to equate expression levels with protein levels.
For example it may be interesting to determine whether the SNPs
we identified are associated with protein levels from stimulated
cells, particularly the inflammatory cytokines, which are known to
be significantly elevated upon stimulation with, for example, the
bacterial membrane antigen lipopolysaccharide [38]. Another
possibility is that associations are caused by nsSNPs that alter
antibody binding affinity, and therefore the measurement of
protein levels. A full re-sequencing effort would be required to rule
this possibility out completely but we note that only two nsSNPs,
D356N, in SHBG, and R1270S in LPA are present in dbSNP, and
neither of these are strongly (r2,0.5) correlated with the most
associated SNPs in our study (both are present in HapMap).
The mechanism of the association between ABO blood group
and TNF-alpha levels is not known and further work is needed to
identify the source of the discrepancy between the associations
when different assays are used. The poor correlation between the
two TNF-alpha measurements in the same study suggests the two
assays are measuring different parts or fractions of the multi-meric
TNF-alpha molecule, which can exist in transmembrane form, as
a freely circulating protein, or as bound to soluble TNF receptors.
Alternatively the association may be caused by cross-reactivity
with ABO antigens. If shown in other studies to have a
physiological effect the association of ABO blood group with
TNF-alpha levels could help the understanding of the mechanisms
behind the associations between blood group O and a reduced risk
of thrombotic related diseases[39] but increased risk of gastric
ulcers[40].
An important implication of our findings is that they may help
dissect the causal direction of the associations between protein
levels and correlated traits. Serum and plasma concentrations of
many proteins change with disease status, ranging from metabolic
and cardiovascular diseases to inflammatory and infectious states.
Often it is not known whether altered levels of proteins are
involved in disease aetiology or are simply a result of the disease
process[12,41]. The identification of genetic variants that alter
protein levels may help dissect these relationships. Given the
relatively small effects that common gene variants usually have on
disease the identification of protein quantitative trait loci (pQTLs)
may be a powerful complementary method of improving our
understanding of disease.
Materials and Methods
Study Participants
InCHIANTI Study. The InCHIANTI study is a population
based sample that includes 298 individuals of ,65 age and 1155
individuals of age $65 years. The study design and protocol have
been described in detail previously [10]. The data collection
started in September 1998 and was completed in March 2000.
The INRCA Ethical Committee approved the entire study
protocol.
Measurement of Proteins. Venipuncture was performed in
the morning after a 12-hour fast. Summary details of mean trait
values and the numbers of individuals those measures were
available in are given in Table 1. Details of the kits used to
measure proteins are given in Table S1 along with intra and inter-
assay coefficients. These assays were done at the INRCA central
laboratory and performed in duplicate and were repeated if the
second measure was more than 10% greater or less than the first.
The average of the two measures was used in the analyses.
Genome-Wide Association Analysis
Genome-wide genotyping was performed using the Illumina
Infinium HumanHap550 genotyping chip (ver1 and ver3 chips
were used). This product assays .555,000 unique SNPs derived
primarily from stages I and II of the International Haplotype Map
Project (www.HapMap.org). Experiments were performed as per
the manufacturers instructions using 750 ng of genomic DNA
extracted from whole blood. After processing chips were scanned
on Illumina BeadStation scanners. All data were analyzed in
BeadStudio (version 3; Illumina), genotype calls were made using
the standard cluster files provided by Illumina. Samples were
initially assessed for genotype success rate (.98%) and concor-
dance of reported and genotype gender. Nine samples were
removed from further analysis due to gender mismatch. Eighty
seven samples failed the cut off genotype success rate of 98%; forty
eight of these samples were re-purified and successfully genotyped,
thus in total 48 samples were removed from further analysis.
Manual checking of genotype clusters was performed for all SNPs
listed in Table 2.
Quality Control
We only used DNA samples for which .98% of all SNPs were
scored. To estimate the ethnicity of each of the InCHIANTI
samples we used the first two principle components from an
EIGENSTRAT[42] analysis of a set of 42,048 independent QC-
ed SNPs (generated using PLINK’s (http://pngu.mgh.harvard.
edu/,purcell/plink/index.shtml) LD-based SNP pruning func-
tion (using parameters –indep-pairwise 200 10 0.1)) that included
InCHIANTI and HapMap CEU, JPT+CHB and YRI samples
(http://www.HapMap.org). Only SNPs with a MAF .10% in
HapMap were used in the analysis. This revealed that all
individuals were of European ancestry (Figure S4). The individuals
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included 20% that were a first degree relative of another person in
the study, as calculated from the Identity by descent (IBD) values
generated by the Plink ‘‘pairwise-IBD’’ function. We corrected for
any over inflation of statistics due to relatedness or residual
population admixture by using an inflation factor for each trait,
generated using EIGENSTRAT[42] (Table S3).
We only used SNPs that were called in .98% of samples and
had minor allele frequencies in our sample of .1%. SNPs
deviating appreciably from the expected population distribution
(Hardy Weinberg Equilibrium p,161024) were also excluded
from the analyses. We calculated how well SNPs passing the QC
criteria covered common variation in the genome by identifying all
European HapMap proxies at r2 $0.8 for minor allele frequencies
(MAF) of 5% and 1%, and then comparing this number to the
HapMap count of all autosomal SNPs $ the MAF.
Individual Genotyping in InCHIANTI
A SNP (rs1799941) previously reported to be associated with
SHBG levels was not present on the Illumina chip or in HapMap.
We therefore genotyped this separately using Taqman probes
(Applied Biosystems).
Statistical Analyses
Protein. Many of the proteins were not normally distributed
and so we performed appropriate statistical transformations.
Where a simple log transformation was not appropriate, we used
the STATA version 9 ‘‘ladder’’ command, which searches a subset
of the ladder of powers to attempt to detect a simple
transformation. Where such simple transformations were not
appropriate (i.e. where the distributions were heavily skewed) we
considered the STATA ‘‘lnskew0’’ command which performs a log
transformation after adding a constant, thus creating a zero-
skewness logged variable. Where this transformation was still not
appropriate we considered the STATA ‘‘bcskew0’’ command
which performs a box-cox power transformation to approximate
normality. For proteins identified as significant using these
transformations we further tested the robustness of the results by
performing a probit transformation: we ranked all individuals for
each trait and assigned Z scores corresponding to percentiles in a
normal distribution.
For eight proteins there were a small percentage of individuals
who had levels below the assay detection limits. In each case there
were less than 13 (1%) individuals with levels below detectable
limits, except for Macrophage inflammatory protein beta, for
which there were 77 individuals below the detectable limits. The
values for these individuals for these traits were coded as zero. For
a ninth protein, TNF-alpha, there were seven individuals who had
levels above the assay detection limits and the values for these
individuals were coded at the maximum detectable value
39.4 pgml-1. Non-parametric analyses using quantile regression
in Stata v9.0, for MIP-beta and TNF-alpha showed that the highly
significant associations observed with these two markers were not
affected by the inclusion of individuals with levels out of the assay
range.
For six proteins (Interferon-G, Interleukin-10, Interleukin-12,
Interleukin-1b, Interleukin-8 and Monocyte Chemoattractant
Protein -1) there were .8% of individuals that had levels below
the detectable limits. For these we dichotomized traits at the
median, or if there was more then 50% below detectable limits, at
this point. There was no transformation which made LipoproteinA
normally distributed but 14 mg/dl is used as a standard clinical
cut off point for high levels and so was used to dichotomise the
variable.
Genome-Wide Association Statistics. For each autosomal
SNP for each of the 36 proteins with levels as quantitative traits,
we performed linear regression using PLINK software with age
and sex as covariates. This means we tested just one genetic model,
an additive model with one degree of freedom. This model tests if
the trait alters by equal amounts with each additional allele across
the three genotypes. For the six markers dichotomized into high
and low values we also performed a single per allele test across
genotypes using PLINK (Cochran-Armitage 1df test for trend).
Permutation Testing and Quantile Regression. To assess
empirical significance of SNPs reaching significance after
Bonferroni correction, we used the maxT function in PLINK.
Full details are available at http://pngu.mgh.harvard.edu/
,purcell/plink/index.shtml but briefly each permutation
randomly swaps phenotype values between individuals to
provide a new dataset sampled under the null hypothesis, but
which preserves any correlation between genotypes. The program
then compares each observed test statistic against the maximum of
all permuted statistics (i.e. over all SNPs) for each single replicate.
For the trans effect we performed 10,000 permutations across the
entire genome and for the cis effects we performed 100,000
permutations across the region (‘‘region-wide’’) containing the
gene and 300 kb each side. This approach meant that
permutation tests were not corrected for relatedness but given
the relatively small inflation factors for each trait and the fact that
the largest permutation p value in Table 2 is 0.0038 this is unlikely
to affect the results appreciably. To further check the robustness of
our findings we performed non-parametric analyses using quantile
regression in Stata v9.0. Three SNPs exceeded the Bonferroni
thresholds for significance, rs11574783 with GP130 levels,
rs2170436 with parathyroid hormone levels (both cis) and
rs1880887 with alkaline phosphatase levels (trans) but these
associations did not remain after either permutation (p.0.05) or
non-parametric tests (p.0.05 after multiplication by number of
SNPs).
False Discovery Rates
To assess false discovery rates we calculated the equivalent q
statistic as implemented in the ‘‘Qvalue’’ software [33] and using a
single file of p values from all 496,032 SNPs for all 42 phenotypes.
ABO Blood Group Determination
The 3 major ABO blood groups are determined by SNPs in the
ABO gene[43]: the O blood group polymorphism (rs8176719) is a
G deletion which generates a premature termination codon, and is
recessive. B blood group differs from A at 7 nucleotides, including
4 non-synonymous SNPs. There were two independent signals in
the ABO gene, associated with TNF-alpha levels (best SNPs were
rs8176746 and rs505922). rs8176746 is one of the 4 non-
synonymous polymorphisms determining the B group and the A
allele, which changes a leucine to methionine amino acid, is found
on all B haplotypes. The O blood group deletion polymorphism
was not present on the Illumina chip and so to accurately
determine ABO blood group, the O deletion polymorphism was
typed in the InCHIANTI samples. The deletion was typed using a
Taqman end-point PCR custom assay designed by Applied
Biosystems. 20ng of DNA was amplified with 1ml of ABsolute
QPCR mix containing ROX reference dye (ABgene) and,
following 40 cycles of PCR, fluorescence was measured on a
Pherastar plate reader and genotypes assigned with Klustercaller
software. Haplotypes were constructed using the B blood group
SNP (rs8176746) and the recessive deletion polymorphism for O
blood group (rs8176719) (Figure S2). Exactly the same methods
were used to assign ABO blood groups to the Health ABC
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samples, except the lack of genome-wide scan data meant we
genotyped both rs8176719 and rs8176746 using Applied Biosys-
tems Taqman assays.
Replication Studies
Summary details of replication studies are given in Table S2. All
individuals are of white European ancestry. To replicate the
SHBG finding we used baseline data from the Weston Area T3/
T4 Study (WATTS) cohort consisting of people on thyroxine
replacement, recruited from GP practices in the Bristol and
Weston-super-Mare areas in the West of England between March
2000 and June 2002. Further details have been previously
published [44]. We also used The Northern Finland 1966 Birth
Cohort (NFBC1966), a study of offspring born in the two
northern-most provinces of Finland to mothers with expected
dates of delivery in 1966[45]. The subjects included in this analysis
are from a subset of individuals who had data taken and DNA
extracted aged 31 years[46,47] To replicate the TNF-alpha
finding we used baseline data from The Health Aging and Body
Composition study, which is an ongoing prospective study
designed to investigate the effect of changes in body composition
and weight-related health conditions on incident functional
limitation. Use of baseline levels of TNF-alpha have been
previously reported [48]. In each case, the serum measure was
transformed to normality before testing an additive genetic model
with age and sex as covariates. Inverse variance meta-analysis as
implemented with the ‘‘metan’’ command in STATAv9.0 was
used to combine associations from across studies. In each
replication study genotyping call rates exceeded 98% and SNPs
were in Hardy Weinberg equilibrium (p.0.05).
Accession Numbers
Accession numbers for proteins are taken from Swissprot
(http://www.ebi.ac.uk/swissprot/): SHBG - PO4278, TNFa -
PO1375, IL-6sR - P08887, MIPb - P13236, IL18 - Q14116, LPA -
P08519, GGT1 - P19440, CRP - P02741, IL1RA - P18510.
Accession numbers for genes are taken from Ensembl (http://
www.ensembl.org/index.html): ABO - ENSG00000175164, IL6R
- ENSG00000160712, CCL4L2 - ENSG00000129277, IL18 -
ENSG00000150782, LPA - ENSG00000198670, GGT1 -
ENSG00000100031, SHBG - ENSG00000129214, CRP -
ENSG00000132693, IL1RN - ENSG00000136689.
Supporting Information
Figure S1 Plots represent box-plots except for LPA where
proportions in high and low groups are given. For each genotype
the box is bordered at the 25th and 75th percentiles with a median
line at the 50th percentile. Horizontal lines joined to the boxes by
vertical lines are calculated utilizing the interquartile range (IQR)
which is the difference between the first and third quartile values
(Q3-Q1). The upper value is the largest data value that is less than
or equal to the third quartile plus 1.56IQR and the lower adjacent
value is the smallest data value that is greater than or equal to the
first quartile minus 1.56IQR. Values exceeding the upper and
lower adjacent values are called outside values and are displayed as
markers. a) Cis effects b) Trans effect.
Found at: doi:10.1371/journal.pgen.1000072.s001 (0.04 MB
DOC)
Figure S2 A) Map of ABO gene from UCSC genome browser,
May04, showing positions of the Illumina panel genotyped SNPs
(rs8176746 and rs505922) and the functional O blood group
polymorphism (rs8176719). b) Linkage disequilibrium (r2) between
the 3 SNPs after the O deletion was typed separately in the
InCHIANTI samples. c) The four haplotypes formed by the three
SNPs shows how rs505922 splits the A blood group allele
haplotype. d) Haplotypes formed by rs8176746 and rs8176719
(the B blood group SNP and the recessive deletion polymorphism
that defines O blood group, respectively) and how they define
ABO phenotype.
Found at: doi:10.1371/journal.pgen.1000072.s002 (0.13 MB
DOC)
Figure S3 Comparison of TNFA results in InCHIANTI. A)
Correlations between transformed TNFA levels (log transforma-
tion) measured using an ELISA method (R&D systems,
HSTA00C) and a LINCOplex method, (Luminex (HADK2-61K-
B). B) Correlations between each of the two transformed TNFA
measures and three other key proteins, IL6 levels, high sensitivity
C reactive protein levels and albumin levels. C) i)–ii)Histograms of
raw TNFA measures, iii)–iv)associations with ABO blood group
shown as box plots; and v) associations of R&D systems method
with ABO blood group showing association is strongest in the one
third of individuals with highest TNFA levels.
Found at: doi:10.1371/journal.pgen.1000072.s003 (0.09 MB
DOC)
Figure S4 InCHIANTI and HapMap samples plotted for the
first two principal components obtained from multidimensional
scaling of a matrix of ‘‘identity by state’’ genotypes. All
InCHIANTI samples cluster tightly around the European
HapMap samples. INCH= InCHIANTI samples, CEU,
JPT+CHB and YRI=European, combined Japanese and Han
Chinese and Yoruban samples from HapMap, respectively.
Found at: doi:10.1371/journal.pgen.1000072.s004 (0.04 MB
DOC)
Table S1 Summary details of participants and mean traits.
Abbreviations for proteins are included if they are used elsewhere.
Found at: doi:10.1371/journal.pgen.1000072.s005 (0.10 MB
DOC)
Table S2 Details of SHBG and TNF-alpha replication studies.
Found at: doi:10.1371/journal.pgen.1000072.s006 (0.03 MB
DOC)
Table S3 Full details of trans and cis effects for 42 proteins. For
the nine regions reaching overall significance we include all SNPs
in that region that cross the significance threshold. IL= interleu-
kin. 3b Trans results. Details of the most strongly associated SNP
in the genome wide scan, excluding the gene coding for the
protein, plus 600 kb of flanking sequence. For TNF-alpha details
of all SNPs in the ABO region ,0.001 are also given.
Found at: doi:10.1371/journal.pgen.1000072.s007 (0.42 MB
XLS)
Table S4 Associations of the eight cis and one trans finding in
InCHIANTI using different covariates and exclusion criteria.
MAF=Minor allele frequency. GC P=p values from table 2 in
the main paper (corrected for the inflation factor given in Table S2,
age and sex). P2=P values correcting for relatedness using
generalized estimating equations, age and sex. P3=P values
correcting for relatedness using generalized estimating equations,
age and sex and using a probit-transformed phenotype. P4=P
values correcting for relatedness using generalized estimating
equations, age, sex, myocardial infarction, diabetes, being a
current smoker, BMI, use of steroids in the last 5 years and use of
lipid lowering treatment in the last five years. P5 =P values
correcting for relatedness using generalized estimating equations,
age, sex, myocardial infarction, diabetes, being a current smoker,
BMI, use of steroids in the last 5 years, and use of lipid lowering
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treatment in the last five years, and additionally the total serum
protein. The number of individuals with missing data for this
number of covariates was small such that N’s for each test were
similar, ranging from 1055 to 1195.
Found at: doi:10.1371/journal.pgen.1000072.s008 (0.04 MB
DOC)
Table S5 Positions of the eight genes with significant cis effects
based on Jan 07, NCBI 35, dbSNP125, HapMap phase II data
release 21a, in relation to the region covered by all HapMap SNPs
tagged at r2.0.2 by the most significant cis effect SNP.
Found at: doi:10.1371/journal.pgen.1000072.s009 (0.04 MB
DOC)
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